Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.
PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
|Colorectal Cancer||Genetic: gene expression analysis Genetic: protein expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy|
- Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Time Frame: 1 month ]
- Gene expression as measured by tissue microarrays [ Time Frame: 1 month ]
- Splice form expression as measured by reverse transcriptase-PCR [ Time Frame: 1 month ]
- VEGF165b protein expression as measured by ELISA [ Time Frame: 1 month ]
|Actual Study Start Date:||July 24, 2007|
|Study Completion Date:||February 1, 2009|
|Primary Completion Date:||February 1, 2009 (Final data collection date for primary outcome measure)|
- Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.
OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897754
|Study Chair:||David Bates, PhD||Bristol Heart Institute at University of Bristol|